• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Buxton Helmsley Issues Letter to Mallinckrodt Plc. Regarding Continued Evidentially False Statements of Financials

    5/12/23 8:00:00 AM ET
    $MNK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MNK alert in real time by email

    The Buxton Helmsley Group, Inc. (together with certain of its affiliates, "BHG" or "we"), the New York City-based investment advisor to clients with financial interests in Mallinckrodt Plc. ("Mallinckrodt" or the "Company") (NYSE:MNK), today issued an open letter (the "Letter") to the Company's Board of Directors, given the Company's continued failure to make required write-downs of asset values where expenses are evidenced, in apparent violation of GAAP ASC 350/360 and Regulation S-X, within its May 9, 2023, Form 10-Q filing with the U.S. Securities and Exchange Commission (the "Commission").

    On March 17, 2023, BHG issued a public report to the Company's Board of Directors (also delivered to the Commission and U.S. Senate Finance Committee), which extensively outlaid and alleged an evidenced multibillion-dollar accounting and securities fraud scheme historically and presently occurring at the Company; uniquely, "strong[ly] evidence[d]" by the Company's own prior-professed standard of determining the fair value of assets securing capital structure interests. Within that March 17, 2023, public report issued by BHG, it was thoroughly laid out how the Company had not only arguably been committing these violations of accounting standards and securities laws long before the Company's Chapter 11 bankruptcy filing on October 12, 2020, but opted to apparently merely resume the scheme of concealing asset value depreciation expenses from the Company's Commission-filed financial statements upon its emergence from reorganization proceedings, in violation of GAAP ASC 350/360 and Regulation S-X.

    Since BHG's March 17, 2023, public report, the Company has neither denied nor rebutted the "strong[ly] evidence[d]" (the Company's own prior-professed evidentiary standard) apparent multibillion-dollar accounting and securities fraud scheme laid out therein.

    Within the Letter today, BHG also highlighted how the Company has now corrected the inaccurate representations related to the licensing/credentials of Chief Financial Officer Bryan Reasons, but only after BHG was forced to publicly notify the Pennsylvania State Board of Accountancy within BHG's April 28, 2023, follow-up letter to the Company (due to the Company's apparent refusal to voluntarily correct the inaccurate representation after BHG's initial March 17, 2023, public letter/report).

    BHG, within the Letter issued today, demanded: 1) the Company restate its May 9, 2023, Form 10-Q filing with the Commission to correct "strong[ly] evidence[d]" apparent violations of GAAP ASC 350/360 and Regulation S-X; 2) the Company restate all historical Commission filings which also contain "strong[ly] evidence[d]" apparent violations of GAAP ASC 350/360 and Regulation S-X, as explicitly outlined within BHG's March 17, 2023, public report; and 3) call an extraordinary general meeting of investors, given the Company's "strong[ly] evidence[d]" apparent insolvency, pursuant to its legal obligation under Ireland's Companies Act of 2014, § 1111, to "deal with the situation" of a net asset deficit.

    The Letter issued by BHG to the Company today, in addition to BHG's March 17 and April 28, 2023, public correspondence, may be found at: https://www.buxtonhelmsley.com/mnk/

    About Buxton Helmsley: The Buxton Helmsley Group, Inc. is a premier financial service, asset management and securities research firm, providing an array of services to a diversified group of individuals, corporations, trusts, and other entities. The firm's headquarters are in New York City.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20230511005825/en/

    Get the next $MNK alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MNK

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MNK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Norton David Y sold $1,334 worth of Ordinary Shares (5,080 units at $0.26), closing all direct ownership in the company

    4 - Mallinckrodt plc (0001567892) (Issuer)

    8/9/21 9:09:30 AM ET
    $MNK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4: O'Neill Hugh M. sold $537 worth of Ordinary Shares (2,100 units at $0.26), decreasing direct ownership by 3% to 76,856 units

    4 - Mallinckrodt plc (0001567892) (Issuer)

    8/9/21 9:10:08 AM ET
    $MNK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4: A Kathy Schaefer disposed of $256 worth of Ordinary Shares (675 units at $0.38), decreasing direct ownership by 3% to 22,934 units

    4 - Mallinckrodt plc (0001567892) (Issuer)

    4/5/21 4:24:38 PM ET
    $MNK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNK
    SEC Filings

    View All

    Mallinckrodt plc filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Mallinckrodt plc (0001567892) (Filer)

    11/5/21 6:01:46 AM ET
    $MNK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mallinckrodt plc filed SEC Form 8-K: Leadership Update

    8-K - Mallinckrodt plc (0001567892) (Filer)

    11/3/21 4:31:03 PM ET
    $MNK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Mallinckrodt plc

    10-Q - Mallinckrodt plc (0001567892) (Filer)

    11/2/21 6:43:01 AM ET
    $MNK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Mallinckrodt Receives Court Approval for "First Day" Motions to Support Ongoing Operations

    Continuing to Serve Customers and Deliver High-Quality Therapies to Patients Without Interruption; Vendors and Suppliers to be Paid in Full in the Ordinary Course DUBLIN, Aug. 30, 2023 /PRNewswire/ -- Mallinckrodt plc (OTC:MNKTQ) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced that it has received approvals from the U.S. Bankruptcy Court for the District of Delaware for its "First Day" motions related to the Company's voluntary Chapter 11 petitions filed on August 28, 2023. As expected, the Court granted Mallinckrodt approval to ac

    8/30/23 11:54:00 AM ET
    $MNK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mallinckrodt plc Takes Next Step to Implement Comprehensive Financial Restructuring Plan to Address Long-Term Debt and Opioid Obligations

    Initiates Voluntary Prepackaged Chapter 11 Proceedings with Overwhelming Support of Key Stakeholders, Including 85%+ of First and Second Lien Debtholders Continuing to Operate Normally, Serve Customers and Deliver High-Quality Therapies to Patients Vendors and Suppliers Expected to be Paid in Full in the Ordinary Course DUBLIN, Aug. 28, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced that it has taken the next step to implement the comprehensive financial restructuring plan contemplated by a Restructuring Support Agreement ("RSA") the Company previously entered into with more than 85% of each of th

    8/28/23 12:17:00 AM ET
    $MNK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mallinckrodt plc Enters into Restructuring Support Agreement with Key Stakeholders on the Terms of a Prepackaged Financial Restructuring Plan

    Agreement Supported by a Substantial Majority of Each of its First and Second Lien Debtholders and Opioid Trust Financial Restructuring Plan to Significantly Reduce Debt, Increase Free Cash Flow Generation, Extend Maturity Runway and Better Position Company for Long-Term Success  Intends to Initiate Voluntary Prepackaged Chapter 11 Proceedings to Implement Plan Continuing to Deliver High-Quality Therapies to Patients and Serve Customers; Vendors and Suppliers to be Paid in Full in the Ordinary Course DUBLIN, Aug. 23, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced it has entered into a Restructur

    8/23/23 8:22:00 AM ET
    $MNK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNK
    Leadership Updates

    Live Leadership Updates

    View All

    Mallinckrodt Announces Appointment of Dr. Peter Richardson, MRCP, as Chief Scientific Officer

    DUBLIN, Jan. 12, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced that Dr. Peter Richardson, B.Med.Sci., BM, BS, MRCP (UK) has been appointed Executive Vice President and Chief Scientific Officer, effective January 12, 2023. With more than 30 years of research and development experience in the pharmaceutical industry, Dr. Richardson will have executive responsibility for Mallinckrodt's branded research and development (R&D), medical affairs, safety, and regulatory affairs functions. He will serve on the Company's Executive Committee and succeeds Steven Romano, M.D., who departed Mallinckrodt in Dece

    1/12/23 6:45:00 AM ET
    $MNK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNK
    Financials

    Live finance-specific insights

    View All

    Mallinckrodt plc Reports First Quarter 2023 Financial Results and Reaffirms Full Year Guidance

    Advanced Launch of Terlivaz® with Rapid and Successful Uptake in Hospital Formulary Access and Continued Medical Community Interest Reports First Quarter Net Sales of $424.6 Million; Net Loss of $249.3 Million; Adjusted EBITDA of $123.5 Million; Diluted Loss Per Share of $18.93 and Adjusted Diluted Earnings Per Share of $1.68 Increased Cash on Hand to $480.0 Million and Reduced Exposure to Interest Rate Volatility Through Interest Rate Cap Agreement, Demonstrating Ongoing Focus on Disciplined Balance Sheet Management Reaffirmed 2023 Net Sales and Adjusted EBITDA Guidance Conference Call and Webcast Today at 8:30 a.m. ET DUBLIN, May 9, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK) ("Malli

    5/9/23 6:45:00 AM ET
    $MNK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mallinckrodt to Report Earnings Results for First Quarter 2023

    DUBLIN, April 24, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK), a global specialty pharmaceutical company, today announced that it will report first quarter 2023 earnings results for the period ended March 31, 2023, on Tuesday, May 9, 2023.  A conference call for investors will begin at 8:30 a.m. ET. The call can be accessed as follows: Live Call Participant Registration (including dial-in): https://register.vevent.com/register/BIbe1f9805fe5b4490acd8359f7bdd616dAudio Only Webcast Link (live and replay):https://edge.media-server.com/mmc/p/24fqexpxAt the Mallinckrodt website

    4/24/23 6:45:00 AM ET
    $MNK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mallinckrodt plc Reports Fourth Quarter and Fiscal 2022 Financial Results and Provides 2023 Guidance

    Made Solid Progress on Launch of Terlivaz® with Significant Medical Community Interest Appointed Chief Scientific Officer with Proven Record of Executing Clinical Programs and Advancing Product Development Pipelines Increased Cash on Hand to $409.5 Million, Underscoring Commitment to Strengthening Balance Sheet and Disciplined Approach to Cost Management Fiscal 2023 Guidance for Adjusted EBITDA is $510 Million to $560 Million Conference Call and Webcast Today at 8:30 a.m. ET DUBLIN, Feb. 28, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today reported results for the fourth quarter ended December 30, 2022. 

    2/28/23 6:45:00 AM ET
    $MNK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Mallinckrodt plc (Amendment)

    SC 13D/A - Mallinckrodt plc (0001567892) (Subject)

    11/12/21 2:55:13 PM ET
    $MNK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Mallinckrodt plc (Amendment)

    SC 13D/A - Mallinckrodt plc (0001567892) (Subject)

    11/5/21 2:58:50 PM ET
    $MNK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Mallinckrodt plc (Amendment)

    SC 13D/A - Mallinckrodt plc (0001567892) (Subject)

    10/22/21 4:48:46 PM ET
    $MNK
    Biotechnology: Pharmaceutical Preparations
    Health Care